Study of 4-drug treatment before surgery for locally advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests a combination of medicines given before surgery (neoadjuvant treatment) for stomach cancer that has grown locally but hasn’t spread to distant organs. It aims to shrink the tumor and improve outcomes by using several drugs together based on tumor features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old, any sex
- Have stomach cancer confirmed by pathology (stomach tumor biopsy/cells), including specific types of adenocarcinoma
- Cancer stage must be at least cT2-4a and/or lymph node positive, and no distant spread (M0)
- Have at least one measurable tumor spot on CT/MRI scan (size cutoffs will be checked)
- Be well enough to get major treatment (ECOG performance status 0–1) and have expected survival over 12 weeks
- Have adequate blood and organ function (enough blood counts, safe liver/kidney tests) and no major prior treatments like chemo, radiation, targeted drugs, or immunotherapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests how well immunotherapy given before surgery (neoadjuvant treatment) works for locally advanced stomach cancer. It aims to improve outcomes by tailoring treatment to different “immunotypes” (how the immune system and tumor behave).
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
This trial tests whether adding two drugs (mecapegfilgrastim and adebrelimab) to standard chemotherapy before surgery can help treat advanced stomach or gastroesophageal junction cancer that has not yet spread. The goal is to shrink the tumor and improve surgical outcomes.
This Phase 2 study tests a combination chemotherapy regimen given before surgery for stomach cancer that cannot be fully removed (unresectable), including spread to lymph nodes. The goal is to shrink the cancer and improve control with a well-known set of medicines given in a specific order.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy drugs (nab-paclitaxel, oxaliplatin, and S-1) plus an immunotherapy drug (sintilimab) given before surgery for younger people (ages 16 to 45) with stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this approach shrinks tumors and improves outcomes.
Hear when a new Locally Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.